Biogen Inc BIIB

$251.65 -1.75 (-0.69%)

Valuation

Market cap
37,457,592,000
Revenue TTM
$9,890,600,000
Net income TTM
$1,292,900,000
P/E (trailing)
21.26
P/E (forward)
20.09
Profit margin
13.07%
Debt to equity
0.39

Trading

Volume
839,700
Avg volume
1,184,350
Day's range
$250.65 – $255.42
Shares out
147,820,000
Stochastic %K
55%
Beta
0.10
Analysts
Moderate Buy
Price target
$268.62

Price

Company profile

Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etan...

Show more

Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE. It offers LEQEMBI for the treatment of Alzheimer's disease; ZURZUVAE for the treatment of postpartum depression; RITUXAN to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for aRelapsed or refractory diffuse large B-cell lymphoma; and other anti-CD20 therapies. Biogen Inc. has collaboration and license agreements with Merz Therapeutics; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; UCB; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis; and Sage Therapeutics, Inc., as well as collaborations with Stoke Therapeutics, Inc. for the development and commercialization of zorevunersen, a disease modifying medicine for the treatment of Dravet syndrome; Dayra Therapeutics, Inc. to develop oral macrocyclic peptides; Vanqua Bio, Inc. for developing Vanqua's preclinical oral C5aR1 antagonist compound; City Therapeutics, Inc. to develop select novel RNAi therapies; and ALTEOGEN Inc. to develop subcutaneous (SC) formulations of biologics utilizing ALT-B4. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Industry
Drug Manufacturers - General
Sector
Healthcare
Phone
617 679 2000
Website
https://www.biogen.com
Address
225 Binney Street, Cambridge, United States

Latest news

Stocktwits

SniperAlphaCom Nov 17, 3:28 AM
$BIIB — The market pulls back, but this one keeps holding near its highs. One of the names flagged by my screener with strong relative strength against the broader index. While $SPY struggled, $BIIB pushed higher and is now building a clean compression box near its recent highs. Price is holding above rising EMAs, with a clear range to work with. That's the kind of setup I like. Defined risk, attractive risk/reward, and no need to chase. I'm watching for a clean breakout to confirm the next leg higher. Anyone else watching $BIIB for a swing?
0 replies
Rayvio_News_Filter Nov 16, 11:01 PM
$ESALF · $BIIB 🏥 Eisai Co., Ltd. and Biogen Inc. presented five-year Clarity AD long-term extension data showing continuous lecanemab reduced the relative risk of progression to the next disease stage by 36% versus ADNI and 62% of low-tau patients improved on CDR-SB at five years. Actionable market event
0 replies
Stocktwits52wHighs Nov 9, 8:16 PM
$BIIB printed a new 52-week high today
0 replies
WAJeff Nov 9, 6:39 PM
$BIIB 10/15 237.96s sold 259.98, $261 52 week high
0 replies
11thestate Nov 9, 1:45 PM
Don't forget that there is also an important settlement to watch for $BIIB We have every detail, including how investors can get paid: https://11th.com/cases/biogen-investor-settlement
0 replies
ForestFoxes Nov 9, 1:07 PM
$ANVS $BIIB $LLY … Dr. Maccecchini should have been in charge of $AVXL submissions to the FDA 😄 (although she mentioned to me in writing that she was “sorry for them” referring to how inferior their drug was compared to her Buntanetap (also known as Posiphen or ANVS-401) … are all CEOs this chatty with retail investors???) Dr. Maccecchini is poaching for money from novice investors and families with loved ones affected by diseases she states that she’s 900% certain her drug works … “gives them hope”. Pumping with false hope … way to go Dr. Maccecchini 👎🏻 P.S. Back in March she had one of her directors publish an article describing her drug’s origins as an “Executioner’s ☠️ Poison”. Can’t make this stuff up 😂🤣😂 https://www.the-scientist.com/buntanetap-from-execution-poison-to-potential-alzheimer-s-disease-drug-74274
0 replies
NolAsrtormZ Nov 9, 12:50 PM
$ANVS Anyone know of any other Phase 3 Alzheimers plays with 6 month data due in March/April 2027 that trade below $1.00 $BIIB $LLY
0 replies
RichboyZan Nov 9, 8:52 AM
$BIIB There’s something here I don’t want to overlook
0 replies